278 related articles for article (PubMed ID: 27960205)
1. The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.
Feldman C; Anderson R
Semin Respir Crit Care Med; 2016 Dec; 37(6):806-818. PubMed ID: 27960205
[No Abstract] [Full Text] [Related]
2. The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy.
Anderson R; Feldman C
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446214
[TBL] [Abstract][Full Text] [Related]
3. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
Ioachimescu OC; Ioachimescu AG; Iannini PB
Int J Antimicrob Agents; 2004 Nov; 24(5):485-90. PubMed ID: 15519482
[TBL] [Abstract][Full Text] [Related]
4. Platelets and Their Role in the Pathogenesis of Cardiovascular Events in Patients With Community-Acquired Pneumonia.
Feldman C; Anderson R
Front Immunol; 2020; 11():577303. PubMed ID: 33042161
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community-acquired pneumonia.
Feldman C; Normark S; Henriques-Normark B; Anderson R
J Intern Med; 2019 Jun; 285(6):635-652. PubMed ID: 30584680
[TBL] [Abstract][Full Text] [Related]
6. Prospective, population-based surveillance of the burden of Streptococcus pneumoniae in community-acquired pneumonia in older adults, Chrzanów County, Poland, 2010 to 2012.
Harat R; Alexander R; Gray S; Gutterman EM; Pluta J; Pride M; Shite S; Fijolek J; Kozub J
Pneumonol Alergol Pol; 2016; 84(2):95-103. PubMed ID: 27238167
[TBL] [Abstract][Full Text] [Related]
7. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease.
Cockeran R; Anderson R; Feldman C
Arch Immunol Ther Exp (Warsz); 2005; 53(3):189-98. PubMed ID: 15995579
[TBL] [Abstract][Full Text] [Related]
8. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.
Jones RN; Jacobs MR; Sader HS
Int J Antimicrob Agents; 2010 Sep; 36(3):197-204. PubMed ID: 20558045
[TBL] [Abstract][Full Text] [Related]
9. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
Yayan J
Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the Top End of the Northern Territory, Australia--over 22 years.
Jacups SP; Cheng A
Vaccine; 2011 Jul; 29(33):5386-92. PubMed ID: 21651943
[TBL] [Abstract][Full Text] [Related]
11. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.
Bordon JM; Fernandez-Botran R; Wiemken TL; Peyrani P; Uriarte SM; Arnold FW; Rodriquez-Hernandez L; Rane MJ; Kelley RR; Binford LE; Uppatla S; Cavallazzi R; Blasi F; Aliberti S; Restrepo MI; Fazeli S; Mathur A; Rahmani M; Ayesu K; Ramirez J
Infection; 2015 Dec; 43(6):729-38. PubMed ID: 26424683
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern.
File TM
Am J Med; 2004 Aug; 117 Suppl 3A(3):39S-50S. PubMed ID: 15360096
[TBL] [Abstract][Full Text] [Related]
13. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies.
Vlachopoulos CV; Terentes-Printzios DG; Aznaouridis KA; Pietri PG; Stefanadis CI
Eur J Prev Cardiol; 2015 Sep; 22(9):1185-99. PubMed ID: 25252595
[TBL] [Abstract][Full Text] [Related]
14. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.
Bordón J; Peyrani P; Brock GN; Blasi F; Rello J; File T; Ramirez J;
Chest; 2008 Mar; 133(3):618-24. PubMed ID: 18198264
[TBL] [Abstract][Full Text] [Related]
15. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
Naito S; Tanaka J; Nagashima K; Chang B; Hishiki H; Takahashi Y; Oikawa J; Nagasawa K; Shimojo N; Ishiwada N
Epidemiol Infect; 2016 Feb; 144(3):494-506. PubMed ID: 26122538
[TBL] [Abstract][Full Text] [Related]
16. Pneumolysin as a potential therapeutic target in severe pneumococcal disease.
Anderson R; Feldman C
J Infect; 2017 Jun; 74(6):527-544. PubMed ID: 28322888
[TBL] [Abstract][Full Text] [Related]
17. Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae.
Cardinal-Fernández P; García Gabarrot G; Echeverria P; Zum G; Hurtado J; Rieppi G
Rev Clin Esp (Barc); 2013 Mar; 213(2):88-96. PubMed ID: 23178082
[TBL] [Abstract][Full Text] [Related]
18. The Binax NOW Streptococcus pneumoniae test applied on nasopharyngeal aspirates to support pneumococcal aetiology in community-acquired pneumonia.
Athlin S; Strålin K
Scand J Infect Dis; 2013 Jun; 45(6):425-31. PubMed ID: 23330980
[TBL] [Abstract][Full Text] [Related]
19. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes.
Cillóniz C; Ewig S; Polverino E; Muñoz-Almagro C; Marco F; Gabarrús A; Menéndez R; Mensa J; Torres A
Clin Microbiol Infect; 2012 Nov; 18(11):1134-42. PubMed ID: 22044658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
